You are here

  • Home
  • Archive
  • Volume 82, Issue 8
  • Response to: Correspondence on ‘Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors’ by Patoulias

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: Correspondence on ‘Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors’ by Patoulias
  1. Marcus Säemann1,2,
  2. Andreas Kronbichler3
  1. 1 6th Medical Department, Nephrology and Dialysis, Clinic Ottakring, Vienna, Austria
  2. 2 Medical School, Sigmund Freud University, Vienna, Austria
  3. 3 Department of Medicine, University of Cambridge, Cambridge, UK
  1. Correspondence to Dr Marcus Säemann, 6th Medical Department, Nephrology and Dialysis, Clinic Ottakring, VIENNA, Austria; SAEMANNMARCUS{at}GMAIL.COM

http://dx.doi.org/10.1136/annrheumdis-2021-221982

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank our colleague Dr Patoulias1 for pointing out that sodium glucose transporter (SGLT)-2 inhibition (SGLT-2i) could mediate nephroprotection in patients with lupus nephritis (LN) and ANCA-associated vasculitis (AAV) via specific mechanisms within the tubular cell compartment independent of the presence of diabetes mellitus.2 As discussed by Dr Patoulias, kidney injury molecule-1 (KIM-1) is affected by SGLT-2i correlating with improvements in albuminuria, a hallmark of …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors MS wrote and submitted the draft. AK edited the first draft of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles